Please contact our sales representative to learn more information about this reagents.
Background
Nesvacumab is an experimental monoclonal antibody originally designed for the treatment of cancer. It targets the protein angiopoietin 2. As of May 2017, it is in Phase II clinical trials for the treatment of diabetic macular edema. This drug is being developed by Regeneron Pharmaceuticals.